Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis (NCT06775340) is a Phase 2 interventional studying Adolescent Asthma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis

What Stage of Research Is This?

Phase 2 trials evaluate whether a treatment actually works against Adolescent Asthma and continue monitoring side effects. Phase 2 enrolls larger groups (typically 100–300 patients) and produces the first real efficacy signal. A successful Phase 2 readout is what unlocks the much larger Phase 3 confirmatory trials needed for FDA approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

Target enrollment of 252 participants puts this in the typical range for a Phase 2-style efficacy study or a moderate Phase 3 trial in a focused Adolescent Asthma subpopulation. At this scale, the study has enough statistical power to detect a clear treatment effect but is not the largest cohort in the field.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age 18-75 years old (including boundary values), male and female. 2. Female subjects weigh ≥45 kg and male subjects weigh ≥50 kg. 3. HRCT shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as NCFB. 4. The expected survival is greater than 12 months. 5. willing to sign a consent form was signed before the trial. 6. Potentially fertile subjects voluntarily take appropriate contraceptive measures. Who Should NOT Join This Trial: 1. Patients with pulmonary hypertension or chronic obstructive pulmonary disease (COPD) or asthma as determined by the investigators were the primary diagnosis were screened. 2. An active, symptomatic infection caused by respiratory viruses, including COVID-19, influenza viruses, etc. 3. Have psoriasis or lichen planus. 4. Have Wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis. 5. Have chlorine acne, large common warts, or keratodermatitis. 6. Has diabetic foot. 7. Have periodontal disease, oral infection, or loose teeth. 8. History of malignant tumor within 5 years prior to screening. 9. Screening subjects with a history of liver disease or currently receiving treatment for liver disease, including but not limited to acute or chronic hepatitis, cirrhosis, or liver failure. 10. Researchers consider any other unstable clinical disease. 11. Oral or inhaled antibiotics were received 4 weeks prior to first administration. 12. Immunosuppressants were administered 4 weeks before the first dose. 13. Received drugs within 4 weeks prior to screening that may cause hyperkeratosis of the skin. 14. Received live attenuated vaccine within 30 days prior to initial administration. 15. Participated in clinical trials of any medical device within 3 months prior to screening. 16. Active hepatitis B virus infection, active hepatitis C virus infection, or known HIV infection or known syphilis infection. 17. Drug abusers. ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Age 18-75 years old (including boundary values), male and female. 2. Female subjects weigh ≥45 kg and male subjects weigh ≥50 kg. 3. HRCT shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as NCFB. 4. The expected survival is greater than 12 months. 5. Informed consent was signed before the trial. 6. Potentially fertile subjects voluntarily take appropriate contraceptive measures. Exclusion Criteria: 1. Patients with pulmonary hypertension or chronic obstructive pulmonary disease (COPD) or asthma as determined by the investigators were the primary diagnosis were screened. 2. An active, symptomatic infection caused by respiratory viruses, including COVID-19, influenza viruses, etc. 3. Have psoriasis or lichen planus. 4. Have Wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis. 5. Have chlorine acne, large common warts, or keratodermatitis. 6. Has diabetic foot. 7. Have periodontal disease, oral infection, or loose teeth. 8. History of malignant tumor within 5 years prior to screening. 9. Screening subjects with a history of liver disease or currently receiving treatment for liver disease, including but not limited to acute or chronic hepatitis, cirrhosis, or liver failure. 10. Researchers consider any other unstable clinical disease. 11. Oral or inhaled antibiotics were received 4 weeks prior to first administration. 12. Immunosuppressants were administered 4 weeks before the first dose. 13. Received drugs within 4 weeks prior to screening that may cause hyperkeratosis of the skin. 14. Received live attenuated vaccine within 30 days prior to initial administration. 15. Participated in clinical trials of any medical device within 3 months prior to screening. 16. Active hepatitis B virus infection, active hepatitis C virus infection, or known HIV infection or known syphilis infection. 17. Drug abusers. 18. Current smoker or former smoker for less than 3 months. 19. Suspected allergy to the investigational product or any component of the investigational product, or severe allergy to any drug, food, toxin or other exposure. 20. Pregnant or lactating women. 21. The subjects were unable to complete the questionnaires due to their limited educational level, or neither the subjects themselves nor their families could fill in the subject log card. 22. The researchers determined that there were other circumstances that were not suitable for participation in this study.

Treatments Being Tested

DRUG

RSS0343 Tabella

RSS0343 tablets, oral;

Locations (1)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT06775340), the sponsor (Jiangsu HengRui Medicine Co., Ltd.), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT06775340 clinical trial studying?

Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis The full protocol is registered on ClinicalTrials.gov and includes the primary outcome measures, eligibility criteria, and study endpoints.

Who can participate in NCT06775340?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT06775340?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT06775340. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT06775340. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.